Rallybio Corporation (NASDAQ:RLYB) Short Interest Update

Rallybio Corporation (NASDAQ:RLYB) was the target of a significant decrease in short interest in the month of September. As of September 15th, there was short interest totaling 422,200 shares, a decrease of 31.1% from the August 31st total of 612,400 shares. Currently, 2.1% of the shares of the company are sold short. Based on an average daily volume of 2,830,000 shares, the short-interest ratio is currently 0.1 days. Based on an average daily volume of 2,830,000 shares, the short-interest ratio is currently 0.1 days. Currently, 2.1% of the shares of the company are sold short.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on RLYB. Wall Street Zen raised Rallybio from a “sell” rating to a “hold” rating in a report on Saturday. Weiss Ratings reissued a “sell (e+)” rating on shares of Rallybio in a report on Saturday, September 27th. Four investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Reduce” and a consensus target price of $5.00.

Rallybio Stock Down 2.4%

Shares of RLYB opened at $0.56 on Wednesday. Rallybio has a 52 week low of $0.22 and a 52 week high of $1.24. The company has a market capitalization of $23.40 million, a price-to-earnings ratio of -0.60 and a beta of -1.10. The stock’s 50-day moving average price is $0.56 and its 200-day moving average price is $0.44.

Rallybio (NASDAQ:RLYB) last issued its earnings results on Thursday, August 7th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.02. Rallybio had a negative return on equity of 71.66% and a negative net margin of 5,473.33%.The firm had revenue of $0.21 million for the quarter. As a group, equities analysts anticipate that Rallybio will post -1.34 EPS for the current fiscal year.

Rallybio Company Profile

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT.